Eli Lilly and Company (LLY) Q1 FY25 earnings call

Eli Lilly delivered a strong Q1 FY25, marked by robust sales of its key growth products, Mounjaro and Zepbound, and positive Phase III data for its oral GLP-1, orforglipron. The company reaffirmed its full-year financial guidance despite significant acquired IPR&D charges and ongoing PBM formulary dynamics impacting Zepbound access. Lilly continues to prioritize manufacturing expansion and pipeline development, aiming to broaden its cardiometabolic franchise and address unmet medical needs, while actively engaging in discussions around external uncertainties like tariffs and drug pricing polic